New members for Anadis' advisory panel

One local and one international scientist have joined the ranks of natural biopharmaceutical developer Anadis (ASX: ANX).

The Campbellfield-based company has announced RMIT University Professor of Food Science Andrew Sinclair and Netherlands Helicobacter pylori specialist Assoc Prof Hans Kusters had been appointed to Anadis' scientific advisory panel.

In an announcement to the market, Anadis said the appointments were recognition of the development of research projects within its portfolio.

The company's focus is on developing new products based on natural substances then applied through innovative delivery systems.

Included in its portfolio are colostrum-derived drugs for the treatment or prevention of conditions including osteoporosis, traveller's diarrhoea and Helicobacter pylori infections.

It is also researching a cartridge device that would use purified bovine antibodies to remove toxins from a patient's blood.

Sinclair's research interest is in neutraceutical foodstuffs, with a focus on the role of a variety of foods and compounds on human health.

Kusters brings to the advisory panel a specialist interest in Helicobacter pylori, the bacteria central to gastric ulcers.

Working out of Rotterdam's Dijkzigt Hospital, Kusters heads an internationally recognised team working the relationship between the bacteria and disease.

The duo will join existing panel members including Prof Colin Chapman, Melbourne Pharmacy College dean, and Prof Frank Dudley, Alfred Hospital head of gastroenterology.

Anadis listed on the Australian Stock Exchange in 1999. At the time of writing its shares were trading at 34 cents.